+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Von Willebrand Disease"

Blood Plasma Derivatives Global Market Report 2024 - Product Thumbnail Image

Blood Plasma Derivatives Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Bleeding Disorders Treatment Global Market Report 2024 - Product Thumbnail Image

Bleeding Disorders Treatment Global Market Report 2024

  • Report
  • December 2023
  • 200 Pages
  • Global
From
From
From
Global Markets for Blood Plasma Products - Product Thumbnail Image

Global Markets for Blood Plasma Products

  • Report
  • February 2023
  • 144 Pages
  • Global
From
Global Non-Cancerous Blood Disease Market Analysis 2021-2031 - Product Thumbnail Image

Global Non-Cancerous Blood Disease Market Analysis 2021-2031

  • Report
  • April 2022
  • 307 Pages
  • Global
From
From
From
Disease Analysis: Hemophilia - Product Thumbnail Image

Disease Analysis: Hemophilia

  • Report
  • June 2021
  • 102 Pages
  • Global
Loading Indicator

Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF), a protein that helps the blood to clot. It is the most common inherited bleeding disorder, affecting both males and females. Symptoms of VWD can range from mild to severe, and include prolonged bleeding from cuts, nosebleeds, and heavy menstrual bleeding. Treatment for VWD typically involves the use of desmopressin, a synthetic form of the hormone vasopressin, and/or replacement therapy with VWF concentrates. The VWD market is a subset of the larger hematology market, which includes treatments for a variety of blood-related disorders. The VWD market is expected to grow due to increasing awareness of the disorder, as well as the development of new treatments. Companies in the VWD market include Shire, CSL Behring, Octapharma, Grifols, and Kedrion. Show Less Read more